NASDAQ: TNXP
Tonix Pharmaceuticals Holding Corp.CIK 0001430306 · SIC 2834 · Pharmaceutical Preparations
Every 8-K is open in full. Other 10-Ks and 10-Qs show a 3-bullet preview. A free account reads 3 more full reports a month. Generating a report requires a verified account.
Sign up freeWant to see a complete report first? Today's free report (HPQ 10-Q) is open in full — no account needed.
Summary not yet generated.
Summary not yet generated.
Partner
Trade TNXP commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Tonix secures GPO agreement expanding TONMYA coverage to 17M commercially insured patients
2 material changes detected. Sign up free to read the summary.
Tonix publishes Phase 1 results showing TNX-1500 blocked immune responses at all doses
3 material changes detected. Sign up free to read the summary.
Tonix presents Phase 1 data for Lyme disease candidate TNX-4800, targets Phase 2 trial in H1 2027
3 material changes detected. Sign up free to read the summary.
Tonix launches first product TONMYA, revenue triples to $6.9M but losses widen to $6.9M
5 material changes detected. Sign up free to read the summary.
Tonix Pharmaceuticals reports Q1 2026 operating results
2 material changes detected. Sign up free to read the summary.
Tonix shareholders authorize reverse stock split up to 1-for-250, approve equity plan
3 material changes detected. Sign up free to read the summary.
revenue $13.1M, net income -$124.0M. Tonix launches first approved drug TONMYA, expands pipeline with Lyme prevention asset
5 material changes detected. Sign up free to read the summary.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Latest financial statements
From 10-Q filed Aug 10, 2026 (period ending Jun 30, 2026). As printed on the EDGAR/iXBRL face — not generated by the model.
Condensed Consolidated Statements of Operations (Unaudited)
(In Thousands, Except Share and Per Share Amounts)
| Description | Three months ended June 30, 2026 | Three months ended June 30, 2025 | Six months ended June 30, 2026 | Six months ended June 30, 2025 |
|---|---|---|---|---|
| REVENUE: | ||||
| Product revenue, net | 13,544 | 1,998 | 20,422 | 4,427 |
| COSTS AND EXPENSES: | ||||
| Cost of sales | 703 | 3,272 | 2,281 | 4,215 |
| Research and development | 19,417 | 10,820 | 37,630 | 18,256 |
| Selling, general and administrative | 35,959 | 16,202 | 64,583 | 26,306 |
| 56,079 | 30,294 | 104,494 | 48,777 | |
| Operating loss | (42,535) | (28,296) | (84,072) | (44,350) |
| Grant income | 600 | 1,036 | 600 | 1,959 |
| Loss on extinguishment of debt | — | — | — | (2,092) |
| Interest income, net | 1,432 | 943 | 2,778 | 1,571 |
| Other expense, net | (49) | (1,955) | (52) | (2,189) |
| Net loss available to common stockholders | (40,552) | (28,272) | (80,746) | (45,101) |
| Net loss per common share, basic and diluted | (2.44) | (3.86) | (5.32) | (6.80) |
| Weighted average common shares outstanding, basic and diluted | 16,635,254 | 7,327,257 | 15,179,268 | 6,631,111 |
Condensed Consolidated Balance Sheets (Unaudited)
(In Thousands, Except Par Value and Share Amounts)
| Description | June 30, 2026 | December 31, 2025 |
|---|---|---|
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | 176,232 | 207,637 |
| Accounts receivable, net | 11,805 | 6,271 |
| Inventory | 4,678 | 6,013 |
| Prepaid expenses and other current assets | 10,717 | 8,955 |
| Total current assets | 203,432 | 228,876 |
| Property and equipment, net | 44,760 | 44,456 |
| Operating lease right-of-use assets | 1,346 | 1,544 |
| Other non-current assets | 4,550 | 2,295 |
| Total assets | 254,088 | 277,171 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||
| Current liabilities: | ||
| Accounts payable | 9,051 | 8,114 |
| Accrued expenses and other current liabilities | 21,484 | 22,598 |
| Lease liability, short term | 250 | 125 |
| Total current liabilities | 30,785 | 30,837 |
| Lease liability, long term | 1,022 | 1,184 |
| Total liabilities | 31,807 | 32,021 |
| Commitments and contingencies (See Note 16) | ||
| Stockholders’ equity: | ||
| Preferred stock, $0.001 par value; 5,000,000 shares authorized, 0 shares issued and outstanding as of both June 30, 2026 and December 31, 2025 | — | — |
| Common stock, $0.001 par value; 1,000,000,000 shares authorized; 16,792,317 and 12,788,069 shares issued and outstanding as of June 30, 2026, and December 31, 2025, respectively and 5,883 shares to be issued as of December 31, 2025 | 17 | 13 |
| Additional paid in capital | 1,158,073 | 1,100,141 |
| Accumulated deficit | (935,461) | (854,715) |
| Accumulated other comprehensive loss | (348) | (289) |
| Total stockholders’ equity | 222,281 | 245,150 |
| Total liabilities and stockholders’ equity | 254,088 | 277,171 |
Condensed Consolidated Statements of Cash Flows (Unaudited)
(In Thousands)
| Description | Six months ended June 30, 2026 | Six months ended June 30, 2025 |
|---|---|---|
| CASH FLOWS FROM OPERATING ACTIVITIES: | ||
| Net loss | (80,746) | (45,101) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation and amortization | 1,174 | 976 |
| Inventory write-off | — | 2,280 |
| Amortization of debt discount | — | 65 |
| Loss on extinguishment of debt | — | 2,092 |
| Stock-based compensation | 4,226 | 2,305 |
| Issuance costs from derivative instruments | — | 1,837 |
| Changes in operating assets and liabilities: | ||
| Accounts receivable | (5,534) | 1,363 |
| Inventory, current and non-current | (534) | 142 |
| Prepaid expenses and other current assets | (1,763) | (483) |
| Other non-current assets | (2,169) | — |
| Accounts payable | 937 | 2,711 |
| Lease liabilities and right-of-use (ROU) asset, net | 160 | (12) |
| Accrued expenses and other current liabilities | (312) | 413 |
| Net cash used in operating activities | (84,561) | (31,412) |
| CASH FLOWS FROM INVESTING ACTIVITIES: | ||
| Issuance of note | — | (2,012) |
| Purchase of property and equipment | (2,279) | (533) |
| Net cash used in investing activities | (2,279) | (2,545) |
| CASH FLOWS FROM FINANCING ACTIVITIES: | ||
| Repurchase of common stock | — | (5,949) |
| Proceeds from ESPP | 79 | — |
| Proceeds from the exercise of options | 16 | — |
| Payment of term loan | — | (9,650) |
| Proceeds, net of $1,725 and $2,757 expenses, from sale of common stock | 53,615 | 76,125 |
| Net cash provided by financing activities | 53,710 | 60,526 |
| Effect of currency rate change on cash | (58) | (13) |
| Net (decrease) increase in cash, cash equivalents and restricted cash | (33,188) | 26,556 |
| Cash, cash equivalents and restricted cash beginning of the period | 209,807 | 99,680 |
| Cash, cash equivalents and restricted cash end of period | 176,619 | 126,236 |
| Supplemental disclosures of cash flow information: | ||
| Interest paid | — | 117 |
| Non-cash financing and investing activities: | ||
| Issuance costs from derivative instruments | — | 1,837 |
| Net ATM proceeds received after quarter-end | — | 1,629 |
| Purchases of property and equipment included in accounts payable and accrued liabilities | 63 | 526 |
Amounts as printed on the EDGAR/iXBRL face — (In Thousands, Except Share and Per Share Amounts); (In Thousands, Except Par Value and Share Amounts); (In Thousands). Labels, columns, and figures are the filing face, not a GAAP stencil. Interactive statements & notes on EDGAR ↗